Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia
British Journal of Haematology · 2023-06 · 201 (5) · 874-886
DOI: 10.1111/bjh.18715 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 10.03.2023. Verfasst von Noomi Vainer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second‐line treatment. In this study, overall survival (OS), treatment‐free survival (TFS) and adverse events (AE) were registered retrospectively in a Danish population‐based cohort upon second‐line treatment for CLL. Data were collected from medical records and the Danish National CLL register. For 286 patients receiving second‐line treatment, three‐year TFS was higher upon targeted treatment (ibrutinib/venetoclax/idelalisib) [63%, 95% confidence interval (CI) 50%–76%] compared with fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab (FCR/BR) (37%, CI: 26%–48%) and chlorambucil+/−CD20‐antibody (CD20Clb/Clb) (22%, CI: 10%–33%). Upon targeted treatment, three‐year OS estimates were higher for targeted treatment (79%, CI: 68%–91%) compared with FCR/BR (70%, CI: 60%–81%) or CD20Clb/Clb (60%, CI: 47%–74%). The most common AEs were infections and haematological AEs; 92% of patients treated with targeted drugs had AEs, 53% of which were severe. Upon FCR/BR and CD20Clb/Clb, AEs were present for 75% and 53% respectively, of which 63% and 31% were severe. These real‐world data demonstrate higher TFS and a tendency towards higher OS following targeted second‐line treatment for CLL compared to chemoimmunotherapy, also for patients who may be frailer and more comorbid.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Pharmacology, Bisbebjerg Hospital, Copenhagen, Denmark.
- Department of Hematology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.
- Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
ORCID-Profile: Noomi Vainer, Kathrine Aarup, Michael Asger Andersen, Henrik Frederiksen, Christian Bjørn Poulsen, Carsten U Niemann, Emelie C Rotbain
Zitieren
APA
Vainer, N., Aarup, K., Andersen, M. A., Wind-Hansen, L., Nielsen, T., Frederiksen, H., Enggaard, L., Poulsen, C. B., Niemann, C. U., & Rotbain, E. C. (2023). Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 201(5), 874-886. https://doi.org/10.1111/bjh.18715
Vancouver
Vainer N, Aarup K, Andersen MA, Wind-Hansen L, Nielsen T, Frederiksen H, et al. Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 2023;201(5):874-886. doi:10.1111/bjh.18715
BibTeX
@article{Vainer2023,
author = {Vainer, Noomi and Aarup, Kathrine and Andersen, Michael Asger and Wind-Hansen, Lise and Nielsen, Tine and Frederiksen, Henrik and Enggaard, Lisbeth and Poulsen, Christian Bjørn and Niemann, Carsten U and Rotbain, Emelie C},
title = {Real‐world outcomes upon second‐line treatment in patients with chronic lymphocytic leukaemia},
journal = {British Journal of Haematology},
year = {2023},
volume = {201},
number = {5},
pages = {874--886},
doi = {10.1111/bjh.18715}
}
EUVIMED